Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 4/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.41 |
| ▸ | ABL1 | P00519 | 3/20 | 0.41 |
| ▸ | BCR | P11274 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.37 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2202372 | 0.92 | KDR (0.47) | RORCMKNK1MKNK2ABL1BCR | |
| SCHEMBL2202042 | 0.91 | KCNJ5 (0.39) | RORCMKNK1MKNK2KDRMAPT | |
| SCHEMBL2203087 | 0.91 | MKNK2 (0.50) | RORCMKNK1MKNK2ABL1BCR | |
| SCHEMBL2202767 | 0.90 | KDR (0.45) | RORCMKNK1MKNK2ABL1BCR | |
| SCHEMBL1408215 | 0.88 | MKNK2 (0.52) | MKNK1MKNK2ABL1BCRMAPT | |
| SCHEMBL2201474 | 0.83 | ABL1 (0.41) | MKNK1MKNK2ABL1KDRMAPT | |
| SCHEMBL2202471 | 0.83 | KDR (0.44) | RORCMKNK1MKNK2ABL1KDR | |
| SCHEMBL1408584 | 0.82 | MAPT (0.46) | RORCMKNK1MKNK2ABL1BCR | |
| SCHEMBL2202884 | 0.82 | MKNK2 (0.42) | RORCMKNK1MKNK2ABL1BCR | |
| SCHEMBL1408439 | 0.81 | ABL1 (0.55) | MKNK1MKNK2ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977338-B2 | Phenylacetamides being FLT3 inhibitors | NOVARTIS AG (CH) | 2011-07-12 | — | — | US | claimed |
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | claimed |
| CN-101558068-A | Phenylacetamides useful as protein kinase inhibitors | NOVARTIS AG (CH) | 2009-10-14 | — | — | CN | claimed |
| US-7977338-B2 | Phenylacetamides being FLT3 inhibitors | NOVARTIS AG (CH) | 2011-07-12 | — | — | US | disclosed |
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | disclosed |
| CN-101558068-A | Phenylacetamides useful as protein kinase inhibitors | NOVARTIS AG (CH) | 2009-10-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | FLT3, JAK2, ABL1 | RORC 2712/4885MKNK1 516/4885MKNK2 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.